Clinical data
Trade namesTookad
Other namesWST-09, WST-11
AHFS/Drugs.comUK Drug Information
License data
ATC code
Legal status
Legal status
  • UK: POM (Prescription only) [1]
  • In general: ℞ (Prescription only)
  • 3-[(2S,3S,12R,13R)-8-acetyl-13-ethyl-20-(2-methoxy-2-oxoethyl)-3,7,12,17-tetramethyl-18-(2-sulfoethylcarbamoyl)-2,3,12,13-tetrahydroporphyrin-22,24-diid-2-yl]propanoic acid;palladium(2+)
CAS Number
PubChem CID
CompTox Dashboard (EPA)
Chemical and physical data
Molar mass840.26 g·mol−1
3D model (JSmol)
  • CCC1C(C2=NC1=CC3=C(C(=C([N-]3)C(=C4C(C(C(=N4)C=C5C(=C(C(=C2)[N-]5)C(=O)C)C)C)CCC(=O)O)CC(=O)OC)C(=O)NCCS(=O)(=O)O)C)C.[Pd+2]
  • InChI=1S/C37H45N5O9S.Pd/c1-8-22-17(2)25-16-30-33(21(6)43)19(4)27(40-30)14-26-18(3)23(9-10-31(44)45)35(41-26)24(13-32(46)51-7)36-34(37(47)38-11-12-52(48,49)50)20(5)28(42-36)15-29(22)39-25;/h14-18,22-23H,8-13H2,1-7H3,(H5,38,39,40,41,42,43,44,45,47,48,49,50);/q;+2/p-2/t17-,18+,22-,23+;/m1./s1

Padeliporfin, sold under the brand name Tookad, is a medication for treating men with low-risk prostate cancer, where the cancer affects only one side of the prostate and who have a life expectancy of at least ten years.[2]

Padeliporfin was approved for use in the European Union in November 2017.[2] The active ingredient in Tookad is padeliporfin di-potassium.[2]


Padeliporfin was approved for use in the European Union in November 2017.[2]

In February 2020, the oncologic drugs advisory committee of the US Food and Drug Administration (FDA) voted against approving padeliporfin di-potassium powder for solution for injection, submitted by Steba Biotech, S.A. The proposed indication (use) for the product is for the treatment of men with localized prostate cancer, meeting the following criteria: Stage T1-T2a and prostate specific antigen less than or equal to 10 ng/mL and Gleason Grade Group 1 based on transrectal ultrasound guided biopsy or unilateral Gleason Grade Group 2 based on multiparametric magnetic resonance imaging-targeted biopsy with less than 50 percent of cores positive.[3][4]


  1. ^ "Tookad 183 mg powder for solution for injection - Summary of Product Characteristics (SmPC)". (emc). Retrieved 1 April 2020.
  2. ^ a b c d "Tookad EPAR". European Medicines Agency (EMA). 29 November 2017. Retrieved 1 April 2020.
  3. ^ "Meeting of the Oncologic Drugs Advisory Committee Meeting Announcement". U.S. Food and Drug Administration (FDA). 26 February 2020. Retrieved 1 April 2020. Public Domain This article incorporates text from this source, which is in the public domain.
  4. ^ Landenberger, Lee (26 February 2020). "Too bad for Tookad: FDA adcom votes against Steba's prostate cancer treatment". BioWorld. Retrieved 1 April 2020.

Further reading